Bioavailability of four slow-release theophylline formulations in the beagle dog

Journal of Veterinary Pharmacology and Therapeutics
G D KoritzI J Munsiff

Abstract

Theophylline was administered to six Beagles intravenously (Aminophyllin Injectable, Searle Laboratories) and orally as four sustained-release formulations (Choledyl -SA Tablets, Parke-Davis; Theo-Dur Tablets, Key Pharmaceuticals; Theo-24 Capsules, Searle Laboratories, and Slo-bid Gyrocaps, William H. Rorer, Inc.). Values were determined for mean residence time, mean absorption time, absolute bioavailability, time to peak plasma concentration, and peak plasma concentration normalized to a theophylline dose of 20 mg/kg. In this order the values found for each formulation were: Choledyl (10.2 +/- 1.8 h, 2.8 +/- 2.2 h, 63 +/- 10%, 3.9 +/- 1.0 h, 10 +/- 1.1 micrograms/ml), Theo-Dur (12.1 +/- 5.2 h, 4.9 +/- 5.3 h, 76 +/- 18% 4.7 +/- 3.1 h, 12 +/- 3.7 micrograms/ml), Theo-24 (15.6 +/- 8.9 h, 8.1 +/- 8.4 h, 30 +/- 16%, 3.6 +/- 1.7 h, 3.5 +/- 1.3 micrograms/ml), and Slo-bid (11.9 +/- 1.9 h, 4.4 +/- 1.3 h, 60 +/- 9%, 4 +/- 1.1 h, 8.6 +/- 0.8 micrograms/ml). Choledyl, Theo-Dur and Slo-bid appear to have absorption characteristics which, if given twice daily, would maintain therapeutic plasma concentrations of theophylline between 10 and 20 micrograms/ml in the dog. Of these, Theo-Dur was predicted to provide the least peak:trough fluctua...Continue Reading

References

Apr 1, 1978·Journal of Pharmacokinetics and Biopharmaceutics·K YamaokaT Uno
Oct 19, 1978·The New England Journal of Medicine·M WeinbergerL Bighley
Jan 1, 1983·Pharmacotherapy·L Hendeles, M Weinberger
May 1, 1984·The Journal of Allergy and Clinical Immunology·M Weinberger
Jun 1, 1981·Journal of Veterinary Pharmacology and Therapeutics·B C McKiernanD R Pheris

❮ Previous
Next ❯

Citations

Jan 1, 1989·Veterinary Research Communications·L D Kinabo, Q A McKellar
Dec 1, 1989·Journal of Veterinary Pharmacology and Therapeutics·T E GoetzB C McKiernan
Jun 1, 1992·Journal of Veterinary Pharmacology and Therapeutics·A D Watson
Mar 1, 1993·Journal of Veterinary Pharmacology and Therapeutics·J AlberolaM Arboix
Aug 19, 2007·The Veterinary Clinics of North America. Small Animal Practice·Elizabeth A RozanskiScott P Shaw
Jun 1, 1989·Journal of Veterinary Pharmacology and Therapeutics·J A DyeG D Koritz
Dec 1, 1988·Journal of Veterinary Pharmacology and Therapeutics·I J MunsiffG D Koritz
Mar 1, 1988·Journal of Veterinary Pharmacology and Therapeutics·I J MunsiffC A Neff-Davis
Sep 1, 1992·The Veterinary Clinics of North America. Small Animal Practice·D M Boothe, B C McKiernan
Sep 18, 2007·Journal of the American Veterinary Medical Association·Christine L Guenther-YenkeElizabeth Powell
Apr 13, 2004·Journal of the American Veterinary Medical Association·Jonathan E BachBrendan C McKiernan
Sep 19, 2019·Journal of Veterinary Pharmacology and Therapeutics·Carrie L CavettJennifer M Reinhart
Oct 22, 2003·Journal of Veterinary Medicine. A, Physiology, Pathology, Clinical Medicine·R A HirtR van den Hoven
Jun 27, 2021·Journal of Veterinary Pharmacology and Therapeutics·Jennifer M ReinhartRyan Fries

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Veterinary Pharmacology and Therapeutics
I J MunsiffG D Koritz
Journal of Veterinary Pharmacology and Therapeutics
B C McKiernanD R Pheris
Journal of Veterinary Pharmacology and Therapeutics
A D WatsonI C Martin
Journal of Veterinary Pharmacology and Therapeutics
B C McKiernanD R Pheris
© 2021 Meta ULC. All rights reserved